Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | GCKR | Q14397 | 5/20 | 0.34 |
| ▸ | GCK | P35557 | 4/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561229 | 0.80 | SLC6A2 (0.44) | — | |
| SCHEMBL7519138 | 0.78 | ALDH1A1 (0.34) | CASP3MMP1MMP3MMP7MMP9 | |
| SCHEMBL2298747 | 0.77 | HTR2A (0.41) | — | |
| SCHEMBL6069866 | 0.77 | FPR2 (0.39) | CASP3ALOX5APROCK2 | |
| SCHEMBL4615210 | 0.76 | GPR119 (0.36) | — | |
| SCHEMBL5674603 | 0.76 | MAPT (0.50) | — | |
| SCHEMBL6543170 | 0.75 | HTT (0.42) | — | |
| SCHEMBL27993761 | 0.75 | HTR2A (0.38) | ROCK2 | |
| SCHEMBL4429861 | 0.75 | RAD52 (0.36) | CASP3MMP9 | |
| SCHEMBL18291312 | 0.74 | CHRNB2 (0.48) | CHRNB2CHRNA4ALOX5APROCK2FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| EP-3385262-B1 | 4-(3H-INDOL-5-YL)-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2022-07-13 | — | — | EP | disclosed |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2021-12-02 | — | — | US | disclosed |
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS | 2021-08-17 | — | — | US | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3385262-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | Gan & Lee Pharmaceuticals (CN) | 2018-10-10 | — | — | EP | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | CHRNB2 3117/4885CHRNA4 3878/4885CASP3 1498/4885 |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | CHRNB2 3117/4885CHRNA4 3878/4885CASP3 1498/4885 |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | CHRNB2 3117/4885CHRNA4 3878/4885CASP3 1498/4885 |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CHRNB2 4587/4885CHRNA4 4253/4885CASP3 689/4885 |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | CHRNB2 3117/4885CHRNA4 3878/4885CASP3 1498/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CHRNB2 4521/4885CHRNA4 4194/4885CASP3 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.